WIXOM, Mich., May 8, 2013 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, announced today they have signed a multi-year, national product supply agreement with DaVita, the dialysis division of DaVita HealthCare Partners, Inc. The supply agreement includes a significant increase in the number of DaVita dialysis clinics that will purchase product from Rockwell, and covers a five-year period.
"We are pleased to enter into this agreement and expand our business with DaVita," stated Rob Chioini, Chairman and CEO of Rockwell. "This multi-year supply agreement will significantly expand our business. It includes the conversion to our CitraPure ® concentrate line and provides an avenue for future sales of new Rockwell products."
DaVita is the dialysis division of DaVita HealthCare Partners Inc., a Fortune 500 ® company that, through its operating divisions, provides a variety of health care services to patient populations throughout the United States and abroad. A leading provider of kidney care in the United States, DaVita delivers dialysis services to patients with chronic kidney failure and end stage renal disease. As of December 31, 2012, DaVita operated or provided administrative services at 2,000 outpatient dialysis centers located in the United States serving approximately 153,000 patients. The company also operated 36 outpatient dialysis centers located in five countries outside the United States.About Rockwell Medical Rockwell Medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. Rockwell's lead drug candidate in late-stage clinical development is for the treatment of iron deficiency in dialysis patients and is called Soluble Ferric Pyrophosphate (SFP). SFP delivers iron to the bone marrow of dialysis patients in a non-invasive, physiologic manner via dialysate during their regular dialysis treatment. In completed clinical trials to date, SFP has demonstrated that it can safely deliver sufficient iron to the bone marrow. SFP is nearing completion of its Phase 3 clinical studies (CRUISE-1 and CRUISE-2) and is expected to address an estimated $600M U.S. market.